Itch Clinical Trial
Official title:
Survey on Itch in Outpatients of a University Clinic
Verified date | April 2019 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is to investigate the pruriception (i.e. the perception of the character and intensity of itch), the impact of itch on quality of life, the response to itch and the subjective efficacy and preferences of the different treatment options among patients with different skin diseases. Better insights into these aspects might help to optimize itch treatment in clinical Settings.
Status | Completed |
Enrollment | 300 |
Est. completion date | April 30, 2016 |
Est. primary completion date | April 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - outpatients suffering from itch Exclusion Criteria: - outpatients (suffering from itch) not willing or able to participate |
Country | Name | City | State |
---|---|---|---|
Switzerland | Department of Dermatology, University Hospital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | itch intensity | Questions regarding itch perception (NRS 0-10; 0 = no itch, 10 = worst imaginable itch) experienced at the moment, within the last 7 days, within the last month | single time point assessment at baseline | |
Primary | itch perception | Questions regarding situations in which the itch is especially bad (multiple choice options regarding day time, daily situations, season); objective assessment in which respondents are asked to select answers from the choices offered as a list | single time point assessment at baseline | |
Primary | impact of itch on quality of life | Questions regarding strength of impact of itch on quality of life (NRS 0-10; 0 = no impact, 10 = extreme) | single time point assessment at baseline | |
Primary | quality of sleep | Questions regarding sleep disturbance by itch (Does itch disturb the patient's sleep and/or sleep of other persons? (yes/no)) | single time point assessment at baseline | |
Primary | days missing at work | Approximate number of days missing at work due to itch within last 6 months | single time point assessment at baseline | |
Primary | helpfulness of common itch therapies | Questions regarding helpfulness of common itch therapies (NRS 0-10; 0 = no reduction in itch, 10 = complete reduction of itch; additionally free text options to indicate specific creams, tablets or alternative medicine) |
single time point assessment at baseline | |
Primary | preferred treatment options | Questions regarding preferred treatment options (NRS 0- 10; 0 = unimportant, 10 = most important; including additional free text option) | single time point assessment at baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01683552 -
Aprepitant in the Management of Biological Therapies-related Severe Pruritus
|
Phase 2 | |
Completed |
NCT02075632 -
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
|
Phase 2 | |
Completed |
NCT04515056 -
Characterization of New Human Models of Non-histaminergic Itch
|
N/A | |
Completed |
NCT04076865 -
Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch
|
N/A | |
Completed |
NCT04588532 -
Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch
|
N/A | |
Enrolling by invitation |
NCT05195177 -
Testing Protocol to Efficiently Induce Itch
|
N/A | |
Withdrawn |
NCT03943407 -
Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch
|
N/A | |
Completed |
NCT04858360 -
Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens
|
N/A | |
Completed |
NCT04635254 -
The Effect of Halophyte-based Cream on Pain and Itch
|
N/A | |
Not yet recruiting |
NCT06201715 -
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
|
N/A | |
Completed |
NCT06036589 -
Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch
|
N/A | |
Completed |
NCT04554888 -
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor
|
N/A | |
Completed |
NCT04387851 -
Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
|
||
Completed |
NCT03928223 -
The Color of Itch; Itch Modification by Color Viewing
|
||
Not yet recruiting |
NCT06245564 -
Effect of Ketamine, Amitriptyline and Their Combination on Histaminergic and Non-histaminergic Itch
|
N/A | |
Completed |
NCT03576053 -
A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing
|
N/A | |
Completed |
NCT04700007 -
Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)
|
N/A | |
Terminated |
NCT02828787 -
Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.
|
N/A | |
Not yet recruiting |
NCT04197440 -
Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch
|
N/A | |
Completed |
NCT04115462 -
A Relation of Morphine-induced Itch and Pain Processing
|
N/A |